- Safety, pharmacokinetics, and pharmacodynamics of single doses of LXR-623, a novel liver X-receptor agonist, in healthy participantsArie Katz
500 Arcola Road, A 3, Collegeville, PA 19426, USA
J Clin Pharmacol 49:643-9. 2009..Central nervous system-related adverse events were observed at the 2 top doses tested. The pharmacodynamic effects described here are the first demonstration of "target engagement" by an LXR agonist in humans...